Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)


Volume 21, 38 Issues, 2014


Download PDF Flyer




Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 9th of 58 in Chemistry & Medicinal
  • 49th of 254 in Pharmacology & Pharmacy
  • 96th of 291 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.715
5 - Year: 4.239

Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings

Author(s): L. Lu, J. Shi, Q. Li, X. Peng, L. Dong, Y. Li, P. Dai, Y. Wang, E. Guo, F. Zhou and Z. Liu

Affiliation: School of Pharmaceutical Sciences, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, China.

Abstract

Metabolizing and eliminating toxic chemicals in the liver are key processes in the body’s defense system. Drug-metabolizing enzymes (DMEs) play central roles in such processes. The activity and expression of several key DMEs are changed in various liver diseases and thus lead to significantly altered drug disposition. This phenomenon severely affects the pharmacotherapy of clinical medications in terms of the safety and efficacy of drug responses. This review highlights liver physiological functions, altered DMEs, and altered drug disposition in liver diseases. Moreover, the implications of changes in DMEs on the fate of clinically relevant drugs are also discussed. Pregnane X receptor and constitutive androstane receptor are two liver-enriched nuclear receptors originally defined as xenobiotic sensors that affect regulation of DMEs. Altered regulation of DMEs in liver diseases contributes to the development of powerful in vitro and in vivo tools to predict drug responses and options for improved drug delivery and development. Although a number of treatment drugs are available for liver diseases, they are limited by their low drug concentration in the target site, presence of side effects, and instability in the human body. The nanoparticle drug delivery system has recently attracted research attention because of its potential to offer solutions to current obstacles that involve the use of therapeutic drugs for liver diseases. Conclusively, this review aims to improve understanding on the regulation of DMEs in liver diseases and on corresponding implications in drug disposition, including novel therapeutic medications.

Keywords: Drug disposition, drug-metabolizing enzymes, liver diseases, nanoparticles, nuclear receptors, pharmacotherapy agents.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 21
Issue Number: 22
First Page: 2522
Last Page: 2541
Page Count: 20
DOI: 10.2174/0929867321666131212144016
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science